Hiroki Kondou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiroki Kondou has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Kazuhiko Bessho
Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
2 shared publicationsTakeshi Kimura
Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
2 shared publicationsAkiko Konishi
Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
1 shared publicationAkira Kanamura
Department of Pharmacology II, Faculty of Medicine Osaka University, Yamadaoka 2-2, Suita 565, Japan
1 shared publicationAtsuko Nakazawa
Department of Clinical Research, Saitama Children’s Medical Center, Saitama, Japan
1 shared publicationAyano Inui
Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama City Tobu Hospital, Kanagawa, Japan
1 shared publication
Latest Publications
- Open Access
- 31 October 2023
- Published by Springer Nature in Research Square
Potentially protein-destabilizing C3 polymorphism in a case of atypical hemolytic uremic syndrome with life-threatening extrarenal manifestations
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disease caused by uncontrolled complement activation. It is frequently associated with a genetic factor including various polymorphisms at the C3 gene locus; however, no functional amino acid substitution in the C-terminal domain has been reported. We experienced a pediatric case of aHUS with multisystem involvements including refractory hypertension and gastrointestinal bleeding in which immunohistochemical, genetic, and molecular structural analyses were performed. Methods: Biopsy specimens were stained for renin and C5b-9. Serum factor Ba levels were measured to evaluate the alternative pathway activation. Genomic DNA was obtained with consent for targeted Sanger sequencing. The possible effects of the identified amino acid substitution on the molecular structure of C3 were analyzed by computer-aided simulation. Results: Immunostaining revealed intense renin staining in the hyperplastic juxtaglomerular apparatus. Endothelial cells of renal and intestinal blood vessels were positive for C5b-9. Serum Ba level in the active phase was higher than control level. Genetic analyses showed a C3 polymorphism resulting in M1604T substitution in the C345C domain. Although previously reported to be a variant of unknown significance, molecular structural analysis indicated that this amino acid substitution results in the formation of a large space within the hydrophobic core of the C-terminal domain, possibly destabilizing the spherical structure of C3. Renin-angiotensin system inhibitors for refractory hypertension were effective in this patient. Conclusions: M1604T substitution in the C345C domain of C3 molecule may functionally underlie the observed life-threatening extrarenal manifestations.
- 31 October 2023
- Published by Springer Nature in Research Square
Open AccessPotentially protein-destabilizing C3 polymorphism in a case of atypical hemolytic uremic syndrome with life-threatening extrarenal manifestations
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disease caused by uncontrolled complement activation. It is frequently associated with a genetic factor including various polymorphisms at the C3 gene locus; however, no functional amino acid substitution in the C-terminal domain has been reported. We experienced a pediatric case of aHUS with multisystem involvements including refractory hypertension and gastrointestinal bleeding in which immunohistochemical, genetic, and molecular structural analyses were performed. Methods: Biopsy specimens were stained for renin and C5b-9. Serum factor Ba levels were measured to evaluate the alternative pathway activation. Genomic DNA was obtained with consent for targeted Sanger sequencing. The possible effects of the identified amino acid substitution on the molecular structure of C3 were analyzed by computer-aided simulation. Results: Immunostaining revealed intense renin staining in the hyperplastic juxtaglomerular apparatus. Endothelial cells of renal and intestinal blood vessels were positive for C5b-9. Serum Ba level in the active phase was higher than control level. Genetic analyses showed a C3 polymorphism resulting in M1604T substitution in the C345C domain. Although previously reported to be a variant of unknown significance, molecular structural analysis indicated that this amino acid substitution results in the formation of a large space within the hydrophobic core of the C-terminal domain, possibly destabilizing the spherical structure of C3. Renin-angiotensin system inhibitors for refractory hypertension were effective in this patient. Conclusions: M1604T substitution in the C345C domain of C3 molecule may functionally underlie the observed life-threatening extrarenal manifestations.
- 28 March 2023
- Published by Elsevier in Legal Medicine
- Vol. 63, 102247
A suicide case by hanging without fixing the end of the rope
- 28 March 2023
- Published by Elsevier in Legal Medicine
- Vol. 63, 102247
A suicide case by hanging without fixing the end of the rope
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15380
The high volume center reported detailed characteristics of non‐EoE EGIDs
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15380
The high volume center reported detailed characteristics of non‐EoE EGIDs
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15053
Current management of children with hepatitis C virus mother‐to‐child transmission
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15053
Current management of children with hepatitis C virus mother‐to‐child transmission
- 2 September 2021
- Published by Wiley in Pediatrics International
- Vol. 63 (9) , 1007-1008
Heliobacterpylori infection and extra‐gastric disease in children and adolescents
- 2 September 2021
- Published by Wiley in Pediatrics International
- Vol. 63 (9) , 1007-1008
Heliobacterpylori infection and extra‐gastric disease in children and adolescents
- 24 January 2021
- Published by Wiley in Pediatrics International
- Vol. 63 (1) , 5-6
Transitional care for inflammatory bowel disease in Japan: To overcome barriers and challenges
- 24 January 2021
- Published by Wiley in Pediatrics International
- Vol. 63 (1) , 5-6
Transitional care for inflammatory bowel disease in Japan: To overcome barriers and challenges
- Open Access
- 19 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis
Progressive familial intrahepatic cholestasis (PFIC), a rare inherited disorder, progresses to liver failure in childhood. We have shown that sodium 4-phenylbutyrate (NaPB), a drug approved for urea cycle disorders (UCDs), has beneficial effects in PFIC. However, there is little evidence to determine an optimal regimen for NaPB therapy. Herein, a multicenter, open-label, single-dose study was performed to investigate the influence of meal timing on the pharmacokinetics of NaPB. NaPB (150 mg/kg) was administered orally 30 min before, just before, and just after breakfast following overnight fasting. Seven pediatric PFIC patients were enrolled and six completed the study. Compared with postprandial administration, an approved regimen for UCDs, preprandial administration significantly increased the peak plasma concentration and area under the plasma concentration-time curve of 4-phenylbutyrate by 2.5-fold (95% confidential interval (CI), 2.0–3.0;P = 0.003) and 2.4-fold (95% CI, 1.7–3.2;P = 0.005). The observational study over 3 years in two PFIC patients showed that preprandial, but not prandial or postprandial, oral treatment with 500 mg/kg/day NaPB improved liver function tests and clinical symptoms and suppressed the fibrosis progression. No adverse events were observed. Preprandial oral administration of NaPB was needed to maximize its potency in PFIC patients.
- 19 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Open AccessEffect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis
Progressive familial intrahepatic cholestasis (PFIC), a rare inherited disorder, progresses to liver failure in childhood. We have shown that sodium 4-phenylbutyrate (NaPB), a drug approved for urea cycle disorders (UCDs), has beneficial effects in PFIC. However, there is little evidence to determine an optimal regimen for NaPB therapy. Herein, a multicenter, open-label, single-dose study was performed to investigate the influence of meal timing on the pharmacokinetics of NaPB. NaPB (150 mg/kg) was administered orally 30 min before, just before, and just after breakfast following overnight fasting. Seven pediatric PFIC patients were enrolled and six completed the study. Compared with postprandial administration, an approved regimen for UCDs, preprandial administration significantly increased the peak plasma concentration and area under the plasma concentration-time curve of 4-phenylbutyrate by 2.5-fold (95% confidential interval (CI), 2.0–3.0;P = 0.003) and 2.4-fold (95% CI, 1.7–3.2;P = 0.005). The observational study over 3 years in two PFIC patients showed that preprandial, but not prandial or postprandial, oral treatment with 500 mg/kg/day NaPB improved liver function tests and clinical symptoms and suppressed the fibrosis progression. No adverse events were observed. Preprandial oral administration of NaPB was needed to maximize its potency in PFIC patients.
- 29 August 2018
- Published by Wiley in Hepatology Research
- Vol. 49 (3) , 314-323
CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia
Aim: Bile acid biosynthesis is strictly regulated under physiological conditions. The expression of fibroblast growth factor (FGF) 19 is induced when bile acids bind to the farnesoid X receptor in the intestinal epithelium. Fibroblast growth factor 19 is then transported by the portal flow, causing transcriptional inhibition of cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1), a key enzyme in bile acid biosynthesis, through the extracellular signal‐regulated kinase (ERK) pathway. However, the regulatory mechanisms of these signaling pathways in hepatocytes under chronic cholestasis remain unclear. We investigated the regulation of these signaling pathways in patients with biliary atresia (BA).Methods: We analyzed the regulation of molecules in these signaling pathways using liver and serum samples from eight BA children and four non‐cholestatic disease controls.Results: CYP7A1 mRNA expression was not inhibited in BA microdissected hepatocyte‐enriched tissue (HET) despite high serum bile acid concentrations. The FGF19 protein was synthesized in BA HET, and its serum concentration was elevated. Fibroblast growth factor receptor 4 was phosphorylated in BA livers. However, ERK phosphorylation was significantly reduced. We examined SPRY2 expression to determine how the ERK pathway was inactivated downstream of the FGF receptor; the expression was significantly increased in BA HET.Conclusions: This is the first study to measure the CYP7A1 mRNA levels in human BA HET. Fibroblast growth factor 19 was increased in BA hepatocytes. By focusing on its regulation in hepatocytes, we showed that the FGF19 pathway did not suppress bile acid synthesis, probably due to an altered mechanism involving upregulated SPRY2 in BA patients.
- 29 August 2018
- Published by Wiley in Hepatology Research
- Vol. 49 (3) , 314-323
CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia
Aim: Bile acid biosynthesis is strictly regulated under physiological conditions. The expression of fibroblast growth factor (FGF) 19 is induced when bile acids bind to the farnesoid X receptor in the intestinal epithelium. Fibroblast growth factor 19 is then transported by the portal flow, causing transcriptional inhibition of cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1), a key enzyme in bile acid biosynthesis, through the extracellular signal‐regulated kinase (ERK) pathway. However, the regulatory mechanisms of these signaling pathways in hepatocytes under chronic cholestasis remain unclear. We investigated the regulation of these signaling pathways in patients with biliary atresia (BA).Methods: We analyzed the regulation of molecules in these signaling pathways using liver and serum samples from eight BA children and four non‐cholestatic disease controls.Results: CYP7A1 mRNA expression was not inhibited in BA microdissected hepatocyte‐enriched tissue (HET) despite high serum bile acid concentrations. The FGF19 protein was synthesized in BA HET, and its serum concentration was elevated. Fibroblast growth factor receptor 4 was phosphorylated in BA livers. However, ERK phosphorylation was significantly reduced. We examined SPRY2 expression to determine how the ERK pathway was inactivated downstream of the FGF receptor; the expression was significantly increased in BA HET.Conclusions: This is the first study to measure the CYP7A1 mRNA levels in human BA HET. Fibroblast growth factor 19 was increased in BA hepatocytes. By focusing on its regulation in hepatocytes, we showed that the FGF19 pathway did not suppress bile acid synthesis, probably due to an altered mechanism involving upregulated SPRY2 in BA patients.
- 1 June 1991
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 177 (2) , 734-738
Histamine-induced inositol phosphate accumulation in type-2 astrocytes
- 1 June 1991
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 177 (2) , 734-738
Histamine-induced inositol phosphate accumulation in type-2 astrocytes